Brief: Ose Immunotherapeutics Announces Granting Of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011
17/02/2021 17:58
Feb 17 (Reuters) - Ose Immunotherapeutics SA OSE.PA :
* ANNOUNCES GRANTING OF FIRST EUROPEAN PATENT PROTECTING
ANTI-IL-7
RECEPTOR ANTAGONIST OSE-127/S95011
* PATENT COVERS PRODUCT AND ITS THERAPEUTIC APPLICATIONS IN
AUTOIMMUNE AND INFLAMMATORY DISEASES THROUGH 2037
Source text for Eikon: ID:nBw2FNpCFa
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO